Shares of Lexicon Pharmaceuticals (LXRX) rose more than 5% on Tuesday after the company announced that the FDA accepted its resubmitted new drug application (NDA) seeking approval for sotagliflozin as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD).A final decision is expected by Dec 20, 2024. If approved, the product will be marketed under the brand name Zynquista with a commercial launch expected in early next year.Lexicon had initia ...